EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone ...
EWING, N.J., Aug 04, 2011 (BUSINESS WIRE) -- Antares Pharma, Inc. AIS -7.08% today announced the positive results of a clinical study evaluating VIBEX(TM) MTX, a proprietary auto injector product ...
EWING, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that the U.S. Food and Drug Administration (FDA ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the first patients have been dosed in a clinical study evaluating testosterone enanthate administered weekly by ...
Antares Pharma today reported it received a Notice of Allowance from the U.S. Patent Trade Office on a patent application for the VIBEX QuickShot device. This device is the latest advancement in its ...
Subcutaneous, Self-Administered Methotrexate for Rheumatoid Arthritis Demonstrated Significantly Gre
EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NAS: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is ...
At the 30th Annual Congress of the European Society for Gene and Cell Therapy in Brussels this week, researchers presented both preclinical and clinical ...
Announced acceptance of the OTREXUP™ New Drug Application (NDA) by the Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback